YVANNA A. LOPEZ (PEREZ MOREL)

Sr. Director of Corporate Development & Innovation Fund, Ulta Beauty Chicago, IL

PROUDEST 2022 PROFESSIONAL ACCOMPLISHMENT: In 2022, I am most proud of the launch of Prisma Ventures, Ulta Beauty’s own digital innovation fund. We are working with some of the most disruptive entrepreneurs in the retail space to revolutionize the future of the industry.

PROFESSIONAL GOAL FOR 2023: I have big goals for 2023! Many things are happening in the background, but the one thing I can share is that I aim to lead Prisma Ventures to become the top technology corporate venture capital fund in the beauty space. We have a great pipeline of potential investments, and we are excited about the quality of the partnerships we will have completed by the end of 2023.

Seth Collins

DAVID T. CHEN

Assistant

Vice President, Corporate Development, AT&T Dallas, TX

PROUDEST 2022 PROFESSIONAL ACCOMPLISHMENT: Successfully transitioning into a new role and organizing a team within it. I was previously responsible for overseeing M&A activities for our Latin American operations. Having led and completed the sale of that business unit in Q4 2021, I transitioned to a new role, becoming responsible for all inorganic activity related to wireless spectrum. This involved a new direct team as well as the development of relationships with our network, policy and regulatory peer groups, among others.

PROFESSIONAL GOAL FOR 2023:

Developing more technical expertise and incorporating that knowledge into business cases. At the crux of all our investment opportunities is the underlying financial and business case, which we are consistently fine-tuning. Applying the latest operational insights and learnings into these cases is a critical best practice and one we are constantly evolving. That will be at the forefront of my mind as we optimize the criteria for capital allocation decisions.

VP, Head of Corporate Development, Conduent Fort Lauderdale, FL

PROUDEST 2022 PROFESSIONAL ACCOMPLISHMENT: Conduent’s most significant completed transaction in 2022 was the sale of the Midas suite of healthcare software to Symplr, a Clearlake and Charlesbank portfolio company. This transaction is a textbook example of M&A’s ability to unlock hidden value in a company composed of diverse businesses. Midas’ $72 million of revenue represented less than 2% of Conduent’s total revenue, yet the $340 million consideration paid represented nearly 30% of Conduent’s market cap as of transaction announcement. In addition to monetizing an asset at an attractive valuation, the Midas sale supported Conduent’s portfolio simplification efforts. We eliminated a non-core business that lacked cross-selling or other portfolio benefits, including relative to Conduent’s remaining commercial healthcare offerings.

PROFESSIONAL GOAL FOR 2023:

Conduent intends to continue to drive value through M&A, both through acquisitions and divestitures. Conduent is well-positioned as an acquirer in the current market environment, given our robust business mix, moderate leverage and investor base. Acquisitions will enable acceleration toward our strategic objectives, whether expansion in growth areas or nascent capabilities (e.g., AI, digitalization, automation). At the same time, since we separated from Xerox, divestitures have been an important component in Conduent’s journey as a standalone company, contributing to our business transformation and pivot to growth. Consideration factors include each business’s fit with the remainder of Conduent, contribution toward profitable growth and the ability to succeed as part of Conduent.

Taha Ahmed

Chief Growth Officer, Forbes Jersey City, NJ

PROUDEST 2022 PROFESSIONAL ACCOMPLISHMENT: I created a new division at Forbes with the sole mission of diversifying and accelerating revenue growth. I built a team of more than 20 professionals that will serve as core growth infrastructure for the organization and enable Forbes to drive growth more effectively through M&A, joint ventures, partnerships and new business incubation.

PROFESSIONAL GOAL FOR 2023: Building new businesses and expanding the Forbes brand into new sectors that extend beyond media.

Dan works under extreme pressure and is available 24/7 to make sure transactions close. He has the ability to cover all facets and project manage multiple tasks at any point of time. Most importantly, he is respectful and appreciative of his fellow colleagues, service providers and is overall a nice person—you don’t always find that in the industry. LEGAL

Daniel Nauheim

Chief Growth Officer, Medrina

New York, NY

PROUDEST 2022 PROFESSIONAL ACCOMPLISHMENT: I started in 2019 as the CFO of National Health Rehabilitation, a national sub-acute physiatry (physical medicine and rehabilitation) medical practice. NHR was a founder-owned and -operated practice, which we brought to market in early 2020. We were having management meetings the second week of March 2020, which coincided with the pandemic-related shutdowns. We ultimately put our sale process on hold and reinvested in growing the business. I spearheaded those efforts during this time. Additionally, we invested in our management team and technology infrastructure, which helped drive growth in total enterprise value between our first and second sell-side process. I also spent significant time building an acquisition pipeline and doing diligence on potential targets that we could acquire once we had a balance sheet to transact with.

We brought the company back to market and sold to Integrated Rehab Consultants in the second half of 2021. Post-sale, I became chief growth officer to focus on our deal pipeline and integration efforts. In 2022, I spearheaded our buy-side efforts, including three successful acquisitions, which led us to rebrand as Medrina. These transactions have added 150 practitioners to our organization, resulting in Medrina doubling in size in 12 months.

PROFESSIONAL GOAL FOR 2023: To continue to identify and acquire outcomes-focused healthcare services organizations, which in turn will create a novel healthcare ecosystem yielding optimal patient outcomes while delivering savings to the system as whole.